Authors
Latest:
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall survival is about 45 to 47 months," says Neeraj Agarwal, MD, FACS.
Latest:
When it comes to urology teaching or learning opportunities, just say yes"Despite the uncertain times, I am grateful to be a student in the field of medicine, where compassion is one of the traits that defines its practitioners," says PA student Steffanie Robertus.
Latest:
John Taylor, III, MD, on novel options in NMIBCJohn A. Taylor, III, MD, MS, discussed the new wealth of options in non–muscle invasive bladder cancer, specifically highlighting detalimogene voraplasmid.
Latest:
Unmet Needs and Treatment Gaps in Prostate CancerThe panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.
Latest:
Comparing Leuprolide Formulations in Advanced Prostate CancerIn the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.
Latest:
Study points to increased public interest in vaginal estrogen"What's important here is that there's an increased public interest in this vaginal estrogen therapy," says Elia Abou Chawareb, MD.
Latest:
Management of BCG-unresponsive NMIBC"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.
Latest:
Nadofaragene firadenovec maintains safety, efficacy in real-world population"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.
Latest:
Ellen Cahill, MD, on chaperone use for genitourinary exams"I think it would be really nice if we did have standardized guidelines on who could serve as a chaperone," says Ellen Cahill, MD.
Latest:
Legislation improves accessibility to mental health programs for cliniciansCongress has taken actions aimed at protecting arrangements in which hospitals and other entities provide bona fide mental health improvement, behavioral health improvement, or maintenance programs to physicians and other clinicians.
Latest:
Radium-223 is associated with low rates of AEs, treatment discontinuation for bone metastatic CRPCOf note, 55% of patients received a full course (6 injections) of radium-223 injections, and 67% received 5 of the 6 injections.
Latest:
What are considerations when selecting a neuromodulation technique for OAB?"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne Pelletier Cameron, MD, FRCSC, FPMRS.
Latest:
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBCPanelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Latest:
Mayo study finds dietary habits that may help prevent kidney stones"Knowing the dietary factors that are most important for preventing kidney stone recurrence can help patients and providers know what to prioritize,” said Andrew Rule, MD.
Latest:
Management of recurrent prostate cancer after focal therapyProviders must carefully consider treatment options to align with patient preference.
Latest:
Survey highlights communication gaps with kidney cancer diagnosis and care“This indicates opportunities to improve communication about diagnosis, psychosocial impacts, and clinical trials, as well as biopsies, physical exercise, and patient engagement,” wrote Rachel H. Giles, PhD, and colleagues.
Latest:
Future of BCG in NMIBCPanelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the future of first-line treatment be a noninfectious agent that would be easier to develop and include more data.
Latest:
Paul Sieber, MD, on the future of genetic testing in prostate cancerSieber shares his thoughts on the potential for universal genetic testing to become a standard of care practice for patients with prostate cancer.
Latest:
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC ManagementPanelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Latest:
Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR AlterationPanelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
Experts consider efficacy of fertility restoration vs sperm cryopreservation“While I would hesitate to say that reversal is truly better in terms of efficacy, I think this data suggests that it's at least as good,” says Scott D. Lundy, MD, PhD, HCLD.
Latest:
Financial toxicity is a growing concern in urologic oncology"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
13 tips to keep your patient data safe from hackersHere are 13 cybersecurity measures medical practices can take to protect patient data from hackers.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Practice Management: Expert coding tipsA physician’s goal is to care for patients, but a key part of being able to provide that care is the eternal quest for payment.
Latest:
Gopa Iyer, MD, highlights SURF301 trial of TYRA-300 in mUC"The preliminary results of that study, which is a phase 1/2 dose escalation and dose expansion trial, were presented by Professor Ben Tran last year at the ENA meeting1 and showed a very favorable toxicity profile compared to erdafitinib," says Gopa Iyer, MD.
Latest:
Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination TherapyPanelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.
